"Leiomyoma" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A benign tumor derived from smooth muscle tissue, also known as a fibroid tumor. They rarely occur outside of the UTERUS and the GASTROINTESTINAL TRACT but can occur in the SKIN and SUBCUTANEOUS TISSUE, probably arising from the smooth muscle of small blood vessels in these tissues.
- Fibroid Tumor
- Fibroid Tumors
- Tumor, Fibroid
- Tumors, Fibroid
- Fibroid Uterus
- Uterus, Fibroid
- Fibroma, Uterine
- Fibromas, Uterine
- Uterine Fibroma
- Uterine Fibromas
- Fibroids, Uterine
- Fibroid, Uterine
- Uterine Fibroid
- Uterine Fibroids
- Leiomyoma, Uterine
Below are MeSH descriptors whose meaning is more general than "Leiomyoma".
Below are MeSH descriptors whose meaning is more specific than "Leiomyoma".
This graph shows the total number of publications written about "Leiomyoma" by people in this website by year, and whether "Leiomyoma" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
|Year||Major Topic||Minor Topic||Total|
To return to the timeline, click here.
Below are the most recent publications written about "Leiomyoma" by people in Profiles.
Gene Expression Profile of Uterine Leiomyoma from Women Exposed to Different Air Pollution Levels in Metropolitan Cities of Sao Paulo, Brazil. Int J Mol Sci. 2023 Jan 26; 24(3).
Assessing the Hepatic Safety of Epigallocatechin Gallate (EGCG) in Reproductive-Aged Women. Nutrients. 2023 Jan 09; 15(2).
Quality of life with relugolix combination therapy for uterine fibroids: LIBERTY randomized trials. Am J Obstet Gynecol. 2023 03; 228(3):320.e1-320.e11.
Long-term Relugolix Combination Therapy for Symptomatic Uterine Leiomyomas. Obstet Gynecol. 2022 12 01; 140(6):920-930.
Linzagolix with and without hormonal add-back therapy for the treatment of symptomatic uterine fibroids: two randomised, placebo-controlled, phase 3 trials. Lancet. 2022 09 17; 400(10356):896-907.
Comprehensive Review of Uterine Fibroids: Developmental Origin, Pathogenesis, and Treatment. Endocr Rev. 2022 07 13; 43(4):678-719.
The Functional Role and Regulatory Mechanism of Bromodomain-Containing Protein 9 in Human Uterine Leiomyosarcoma. Cells. 2022 07 10; 11(14).
Human Myometrial and Uterine Fibroid Stem Cell-Derived Organoids for Intervening the Pathophysiology of Uterine Fibroid. Reprod Sci. 2022 09; 29(9):2607-2619.
Relugolix Combination Therapy for Uterine Leiomyoma-Associated Pain in the LIBERTY Randomized Trials. Obstet Gynecol. 2022 06 01; 139(6):1070-1081.
Adverse childhood experiences and health-related quality of life among women undergoing hysterectomy for uterine leiomyoma. Am J Obstet Gynecol. 2022 08; 227(2):351-353.e5.